WO2021096270A1 - Ampk 억제기능과 아연항상성 조절기능에 기반한 다발성 경화증 치료용 약학적 조성물 - Google Patents
Ampk 억제기능과 아연항상성 조절기능에 기반한 다발성 경화증 치료용 약학적 조성물 Download PDFInfo
- Publication number
- WO2021096270A1 WO2021096270A1 PCT/KR2020/015932 KR2020015932W WO2021096270A1 WO 2021096270 A1 WO2021096270 A1 WO 2021096270A1 KR 2020015932 W KR2020015932 W KR 2020015932W WO 2021096270 A1 WO2021096270 A1 WO 2021096270A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- indol
- amino
- thiazol
- group
- methylene
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 47
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 230000007987 cellular zinc ion homeostasis Effects 0.000 title abstract description 14
- 101100321932 Rattus norvegicus Prkaa2 gene Proteins 0.000 title 1
- 230000000694 effects Effects 0.000 claims abstract description 52
- 230000000324 neuroprotective effect Effects 0.000 claims abstract description 6
- 201000002491 encephalomyelitis Diseases 0.000 claims description 65
- 238000011282 treatment Methods 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 45
- 239000001257 hydrogen Substances 0.000 claims description 45
- 229910052736 halogen Inorganic materials 0.000 claims description 32
- 150000002367 halogens Chemical class 0.000 claims description 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 30
- 125000004432 carbon atom Chemical group C* 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 150000001555 benzenes Chemical group 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- 150000002431 hydrogen Chemical class 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 15
- 150000001412 amines Chemical class 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 230000006907 apoptotic process Effects 0.000 claims description 8
- 230000008595 infiltration Effects 0.000 claims description 7
- 238000001764 infiltration Methods 0.000 claims description 7
- -1 iodomethyl Chemical group 0.000 claims description 7
- NAVTWMZPVFNTPU-DEDYPNTBSA-N (5e)-2-(4-butylanilino)-5-(1h-indol-3-ylmethylidene)-1,3-thiazol-4-one Chemical compound C1=CC(CCCC)=CC=C1NC(S1)=NC(=O)\C1=C/C1=CNC2=CC=CC=C12 NAVTWMZPVFNTPU-DEDYPNTBSA-N 0.000 claims description 6
- GFAWRJQPLXEXTM-WOJGMQOQSA-N (5e)-2-(4-methylanilino)-5-[(2-methyl-1h-indol-3-yl)methylidene]-1,3-thiazol-4-one Chemical compound CC=1NC2=CC=CC=C2C=1\C=C(C(N=1)=O)\SC=1NC1=CC=C(C)C=C1 GFAWRJQPLXEXTM-WOJGMQOQSA-N 0.000 claims description 6
- NAVTWMZPVFNTPU-MOSHPQCFSA-N (5z)-2-(4-butylanilino)-5-(1h-indol-3-ylmethylidene)-1,3-thiazol-4-one Chemical compound C1=CC(CCCC)=CC=C1NC(S1)=NC(=O)\C1=C\C1=CNC2=CC=CC=C12 NAVTWMZPVFNTPU-MOSHPQCFSA-N 0.000 claims description 6
- GFAWRJQPLXEXTM-WQRHYEAKSA-N (5z)-2-(4-methylanilino)-5-[(2-methyl-1h-indol-3-yl)methylidene]-1,3-thiazol-4-one Chemical compound CC=1NC2=CC=CC=C2C=1\C=C(C(N=1)=O)/SC=1NC1=CC=C(C)C=C1 GFAWRJQPLXEXTM-WQRHYEAKSA-N 0.000 claims description 6
- ZSIQTUBVHZSGJV-APSNUPSMSA-N 2-hydroxy-5-[[(5z)-5-(1h-indol-3-ylmethylidene)-4-oxo-1,3-thiazol-2-yl]amino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NC=2SC(/C(=O)N=2)=C\C=2C3=CC=CC=C3NC=2)=C1 ZSIQTUBVHZSGJV-APSNUPSMSA-N 0.000 claims description 6
- 208000016192 Demyelinating disease Diseases 0.000 claims description 6
- 206010012305 Demyelination Diseases 0.000 claims description 6
- COBYKQHIOTVEAX-LZYBPNLTSA-N (5e)-2-anilino-5-[(5-bromo-1h-indol-3-yl)methylidene]-1,3-thiazol-4-one Chemical compound C12=CC(Br)=CC=C2NC=C1\C=C(C(N=1)=O)\SC=1NC1=CC=CC=C1 COBYKQHIOTVEAX-LZYBPNLTSA-N 0.000 claims description 5
- OIDVNWLZUNQMBZ-YVLHZVERSA-N (5z)-2-(2-chloroanilino)-5-[(2-methyl-1h-indol-3-yl)methylidene]-1,3-thiazol-4-one Chemical compound CC=1NC2=CC=CC=C2C=1\C=C(C(N=1)=O)/SC=1NC1=CC=CC=C1Cl OIDVNWLZUNQMBZ-YVLHZVERSA-N 0.000 claims description 5
- RZEPNYZLAXOTGZ-MFOYZWKCSA-N (5z)-5-(1h-indol-3-ylmethylidene)-2-(3-methoxyanilino)-1,3-thiazol-4-one Chemical compound COC1=CC=CC(NC=2SC(/C(=O)N=2)=C\C=2C3=CC=CC=C3NC=2)=C1 RZEPNYZLAXOTGZ-MFOYZWKCSA-N 0.000 claims description 5
- ZUOMSEASMNCHHT-CXUHLZMHSA-N 2-[[(5e)-5-(1h-indol-3-ylmethylidene)-4-oxo-1,3-thiazol-2-yl]amino]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1NC(S1)=NC(=O)\C1=C/C1=CNC2=CC=CC=C12 ZUOMSEASMNCHHT-CXUHLZMHSA-N 0.000 claims description 5
- KGKAPVKWSWQHEH-SXGWCWSVSA-N 3-[[(5z)-5-(1h-indol-3-ylmethylidene)-4-oxo-1,3-thiazol-2-yl]amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC=2SC(/C(=O)N=2)=C\C=2C3=CC=CC=C3NC=2)=C1 KGKAPVKWSWQHEH-SXGWCWSVSA-N 0.000 claims description 5
- FYPPZDRNGWYFTL-ZDLGFXPLSA-N (5z)-2-(3,4-dimethylanilino)-5-(1h-indol-3-ylmethylidene)-1,3-thiazol-4-one Chemical compound C1=C(C)C(C)=CC=C1NC(S1)=NC(=O)\C1=C\C1=CNC2=CC=CC=C12 FYPPZDRNGWYFTL-ZDLGFXPLSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- NQYWGLGSFWGKEU-UDWIEESQSA-N (5e)-5-(1h-indol-3-ylmethylidene)-2-(naphthalen-1-ylamino)-1,3-thiazol-4-one Chemical compound C1=CC=C2C(/C=C3/SC(NC=4C5=CC=CC=C5C=CC=4)=NC3=O)=CNC2=C1 NQYWGLGSFWGKEU-UDWIEESQSA-N 0.000 claims description 3
- BYBGUDGDISNFNL-ZDLGFXPLSA-N (5z)-2-(2,3-dimethylanilino)-5-(1h-indol-3-ylmethylidene)-1,3-thiazol-4-one Chemical compound CC1=CC=CC(NC=2SC(/C(=O)N=2)=C\C=2C3=CC=CC=C3NC=2)=C1C BYBGUDGDISNFNL-ZDLGFXPLSA-N 0.000 claims description 3
- YALXONUQCWRJKI-SXGWCWSVSA-N (5z)-2-(2-chloroanilino)-5-(1h-indol-3-ylmethylidene)-1,3-thiazol-4-one Chemical compound ClC1=CC=CC=C1NC(S1)=NC(=O)\C1=C\C1=CNC2=CC=CC=C12 YALXONUQCWRJKI-SXGWCWSVSA-N 0.000 claims description 3
- OUMVWNZVRDEBFS-PXNMLYILSA-N (5z)-2-(3-bromoanilino)-5-(1h-indol-3-ylmethylidene)-1,3-thiazol-4-one Chemical compound BrC1=CC=CC(NC=2SC(/C(=O)N=2)=C\C=2C3=CC=CC=C3NC=2)=C1 OUMVWNZVRDEBFS-PXNMLYILSA-N 0.000 claims description 3
- QEOGBELTJNDPCD-PXNMLYILSA-N (5z)-2-(3-chloroanilino)-5-(1h-indol-3-ylmethylidene)-1,3-thiazol-4-one Chemical compound ClC1=CC=CC(NC=2SC(/C(=O)N=2)=C\C=2C3=CC=CC=C3NC=2)=C1 QEOGBELTJNDPCD-PXNMLYILSA-N 0.000 claims description 3
- UYYDLMHJWWDZEP-PXNMLYILSA-N (5z)-2-(3-hydroxyanilino)-5-(1h-indol-3-ylmethylidene)-1,3-thiazol-4-one Chemical compound OC1=CC=CC(NC=2SC(/C(=O)N=2)=C\C=2C3=CC=CC=C3NC=2)=C1 UYYDLMHJWWDZEP-PXNMLYILSA-N 0.000 claims description 3
- FDROHGNBKPFIAH-SXGWCWSVSA-N (5z)-2-(4-hydroxyanilino)-5-(1h-indol-3-ylmethylidene)-1,3-thiazol-4-one Chemical compound C1=CC(O)=CC=C1NC(S1)=NC(=O)\C1=C\C1=CNC2=CC=CC=C12 FDROHGNBKPFIAH-SXGWCWSVSA-N 0.000 claims description 3
- SIKRWMQLXWFFLY-YBEGLDIGSA-N (5z)-2-anilino-5-(1h-indol-3-ylmethylidene)-1,3-thiazol-4-one Chemical compound S1\C(=C/C=2C3=CC=CC=C3NC=2)C(=O)N=C1NC1=CC=CC=C1 SIKRWMQLXWFFLY-YBEGLDIGSA-N 0.000 claims description 3
- WBJSIZUOYHFQCS-YVLHZVERSA-N (5z)-5-(1h-indol-3-ylmethylidene)-2-(2-methylanilino)-1,3-thiazol-4-one Chemical compound CC1=CC=CC=C1NC(S1)=NC(=O)\C1=C\C1=CNC2=CC=CC=C12 WBJSIZUOYHFQCS-YVLHZVERSA-N 0.000 claims description 3
- HLGFTOPICONZOJ-YVLHZVERSA-N (5z)-5-(1h-indol-3-ylmethylidene)-2-(3-methylanilino)-1,3-thiazol-4-one Chemical compound CC1=CC=CC(NC=2SC(/C(=O)N=2)=C\C=2C3=CC=CC=C3NC=2)=C1 HLGFTOPICONZOJ-YVLHZVERSA-N 0.000 claims description 3
- YEXOYCIZRUADOZ-YVLHZVERSA-N (5z)-5-(1h-indol-3-ylmethylidene)-2-(4-methylanilino)-1,3-thiazol-4-one Chemical compound C1=CC(C)=CC=C1NC(S1)=NC(=O)\C1=C\C1=CNC2=CC=CC=C12 YEXOYCIZRUADOZ-YVLHZVERSA-N 0.000 claims description 3
- JEEDTFSNKVHVEP-SXGWCWSVSA-N (5z)-5-(1h-indol-3-ylmethylidene)-2-[2-(trifluoromethyl)anilino]-1,3-thiazol-4-one Chemical compound FC(F)(F)C1=CC=CC=C1NC(S1)=NC(=O)\C1=C\C1=CNC2=CC=CC=C12 JEEDTFSNKVHVEP-SXGWCWSVSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 230000000451 tissue damage Effects 0.000 claims description 3
- 231100000827 tissue damage Toxicity 0.000 claims description 3
- JLDTWSOKPGRVKL-ZDLGFXPLSA-N (5z)-2-(2,4-dimethylanilino)-5-(1h-indol-3-ylmethylidene)-1,3-thiazol-4-one Chemical compound CC1=CC(C)=CC=C1NC(S1)=NC(=O)\C1=C\C1=CNC2=CC=CC=C12 JLDTWSOKPGRVKL-ZDLGFXPLSA-N 0.000 claims description 2
- GMHKPPISUXEJHE-PXNMLYILSA-N (5z)-5-(1h-indol-3-ylmethylidene)-2-[3-(trifluoromethyl)anilino]-1,3-thiazol-4-one Chemical compound FC(F)(F)C1=CC=CC(NC=2SC(/C(=O)N=2)=C\C=2C3=CC=CC=C3NC=2)=C1 GMHKPPISUXEJHE-PXNMLYILSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 2
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 abstract 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 description 61
- 239000011701 zinc Substances 0.000 description 60
- 229910052725 zinc Inorganic materials 0.000 description 59
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 58
- 241000699670 Mus sp. Species 0.000 description 44
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 29
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 29
- 239000003814 drug Substances 0.000 description 27
- 229940079593 drug Drugs 0.000 description 25
- 230000006698 induction Effects 0.000 description 19
- 210000004885 white matter Anatomy 0.000 description 18
- 229940027941 immunoglobulin g Drugs 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 16
- 210000000274 microglia Anatomy 0.000 description 15
- 230000006870 function Effects 0.000 description 14
- 210000002540 macrophage Anatomy 0.000 description 14
- 230000001988 toxicity Effects 0.000 description 14
- 231100000419 toxicity Toxicity 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- 238000003125 immunofluorescent labeling Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 210000002865 immune cell Anatomy 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 108010050904 Interferons Proteins 0.000 description 8
- 102000014150 Interferons Human genes 0.000 description 8
- 206010033799 Paralysis Diseases 0.000 description 8
- 230000035508 accumulation Effects 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 210000001130 astrocyte Anatomy 0.000 description 8
- 230000008499 blood brain barrier function Effects 0.000 description 8
- 210000001218 blood-brain barrier Anatomy 0.000 description 8
- 229940079322 interferon Drugs 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 7
- 229960005228 clioquinol Drugs 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 6
- UUAQRSIXJGAQGA-UHFFFAOYSA-N FluoZin-3 Chemical compound COc1ccc(N(CC(O)=O)CC(O)=O)c(OCCOc2cc(ccc2NCC(O)=O)-c2c3cc(F)c(O)cc3oc3cc(=O)c(F)cc23)c1 UUAQRSIXJGAQGA-UHFFFAOYSA-N 0.000 description 6
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 6
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 6
- 102100025136 Macrosialin Human genes 0.000 description 6
- 101710159843 Zinc transporter 3 Proteins 0.000 description 6
- 102100034988 Zinc transporter 3 Human genes 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 230000009920 chelation Effects 0.000 description 6
- 210000003618 cortical neuron Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 210000005087 mononuclear cell Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 5
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 5
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 5
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 5
- 102000006386 Myelin Proteins Human genes 0.000 description 5
- 108010083674 Myelin Proteins Proteins 0.000 description 5
- 206010029350 Neurotoxicity Diseases 0.000 description 5
- 206010044221 Toxic encephalopathy Diseases 0.000 description 5
- ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000003492 excitotoxic effect Effects 0.000 description 5
- 231100000063 excitotoxicity Toxicity 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000005012 myelin Anatomy 0.000 description 5
- 210000003007 myelin sheath Anatomy 0.000 description 5
- 231100000228 neurotoxicity Toxicity 0.000 description 5
- 230000007135 neurotoxicity Effects 0.000 description 5
- 230000004792 oxidative damage Effects 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 208000021090 palsy Diseases 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000005779 cell damage Effects 0.000 description 4
- 208000037887 cell injury Diseases 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 230000008045 co-localization Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002964 excitative effect Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 3
- 102000047918 Myelin Basic Human genes 0.000 description 3
- 101710107068 Myelin basic protein Proteins 0.000 description 3
- 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 3
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 3
- 102000004722 NADPH Oxidases Human genes 0.000 description 3
- 108010002998 NADPH Oxidases Proteins 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 210000004884 grey matter Anatomy 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 3
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 230000004572 zinc-binding Effects 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108091006671 Ion Transporter Proteins 0.000 description 2
- 102000037862 Ion Transporter Human genes 0.000 description 2
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 2
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000000942 confocal micrograph Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000002555 ionophore Substances 0.000 description 2
- 230000000236 ionophoric effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- GXEDNWSUKCJLLB-LURJTMIESA-N (2s)-2-amino-4-methylpentane-1-thiol Chemical compound CC(C)C[C@H](N)CS GXEDNWSUKCJLLB-LURJTMIESA-N 0.000 description 1
- 0 *c1c(C=C(C(*2)O)SC2Nc2c(*)c(*)c(*)c(*)c2*)c2cc(*)ccc2[n]1 Chemical compound *c1c(C=C(C(*2)O)SC2Nc2c(*)c(*)c(*)c(*)c2*)c2cc(*)ccc2[n]1 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 108091010877 Allograft inflammatory factor 1 Proteins 0.000 description 1
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 238000010152 Bonferroni least significant difference Methods 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- XLBZDSWPSSIELS-UWVJOHFNSA-N N1C=C(C2=CC=CC=C12)\C=C/1\C(N=C(S\1)NC1=CC2=C(OCO2)C=C1)=C Chemical compound N1C=C(C2=CC=CC=C12)\C=C/1\C(N=C(S\1)NC1=CC2=C(OCO2)C=C1)=C XLBZDSWPSSIELS-UWVJOHFNSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 208000037875 astrocytosis Diseases 0.000 description 1
- 230000007341 astrogliosis Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008280 toxic mechanism Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Definitions
- the present invention relates to a pharmaceutical composition for the treatment of multiple sclerosis, and more particularly, to a pharmaceutical composition for the treatment of multiple sclerosis based on an AMPK inhibitory function and a zinc homeostasis control function.
- MS Multiple sclerosis
- the mechanism is involved.
- the treatment of multiple sclerosis has been mainly steroids and immunosuppressants. This is based on the fact that the main mechanism of multiple sclerosis is an autoimmune mechanism, and it is an attempt to control the disease by weakening the body's immune function.
- the above treatments have a distinct effect in the acute phase of the disease, they do not play a role in suppressing or reducing the recurrence of the disease in the long term.
- beta-globulin is injected through the spinal fluid or skin.
- the downside is that you have to keep receiving it.
- Korean Patent No. 1324647 discloses a composition for treating or preventing multiple neurosclerosis and a screening method thereof.
- LeuSH L-Leucinethiol
- the present invention provides a pharmaceutical composition for the treatment of multiple sclerosis based on an AMPK inhibitory function and a zinc homeostasis modulating function that effectively treats multiple sclerosis due to a neuroprotective effect without side effects. It aims to do.
- these problems are exemplary, and the scope of the present invention is not limited thereby.
- a pharmaceutical composition for the treatment of multiple sclerosis or encephalomyelitis containing a compound having the structure of the following formula 1 as an active ingredient:
- R 1 to R 5 are each independently hydrogen, a hydroxy group, a halogen, a substituted or unsubstituted alkyl group having 1 to 7 carbon atoms, a substituted alkoxy group having 1 to 7 carbon atoms, or an unsubstituted alkoxy group, an amine group.
- a carboxyl group or R 2 and R 3 together form a -O-(CH 2 ) n -O- ring or a substituted or unsubstituted benzene ring (n is an integer of 1 to 3)
- R 6 is hydrogen or a methyl group
- R 7 is hydrogen or halogen, in the above formula Is a single bond or a double bond).
- a method for treating multiple sclerosis in a subject comprising administering to a subject suffering from multiple sclerosis a therapeutically effective amount of a compound having the structure of Formula 1 below:
- R 1 to R 5 are each independently hydrogen, a hydroxy group, a halogen, a substituted or unsubstituted alkyl group having 1 to 7 carbon atoms, a substituted alkoxy group having 1 to 7 carbon atoms or an unsubstituted alkoxy group, amine A group, a carboxyl group, or R 2 and R 3 together form a -O-(CH 2 ) n -O- ring or a substituted or unsubstituted benzene ring (n is an integer of 1 to 3), and R 6 is a hydrogen or methyl group And R 7 is hydrogen or halogen, in the above formula Is a single bond or a double bond).
- a method for treating encephalomyelitis in a subject comprising administering to a subject suffering from encephalomyelitis a therapeutically effective amount of a compound having the structure of Formula 1 below:
- R 1 to R 5 are each independently hydrogen, a hydroxy group, a halogen, a substituted or unsubstituted alkyl group having 1 to 7 carbon atoms, a substituted alkoxy group having 1 to 7 carbon atoms or an unsubstituted alkoxy group, amine A group, a carboxyl group, or R 2 and R 3 together form a -O-(CH 2 ) n -O- ring or a substituted or unsubstituted benzene ring (n is an integer of 1 to 3), and R 6 is a hydrogen or methyl group And R 7 is hydrogen or halogen, in the above formula Is a single bond or a double bond).
- R 1 to R 5 are each independently hydrogen, a hydroxy group, a halogen, a substituted or unsubstituted alkyl group having 1 to 7 carbon atoms, a substituted alkoxy group having 1 to 7 carbon atoms or an unsubstituted alkoxy group, amine A group, a carboxyl group, or R 2 and R 3 together form a -O-(CH 2 ) n -O- ring or a substituted or unsubstituted benzene ring (n is an integer of 1 to 3), and R 6 is a hydrogen or methyl group And R 7 is hydrogen or halogen, in the above formula Is a single bond or a double bond).
- R 1 to R 5 are each independently hydrogen, a hydroxy group, a halogen, a substituted or unsubstituted alkyl group having 1 to 7 carbon atoms, a substituted alkoxy group having 1 to 7 carbon atoms or an unsubstituted alkoxy group, amine A group, a carboxyl group, or R 2 and R 3 together form a -O-(CH 2 ) n -O- ring or a substituted or unsubstituted benzene ring (n is an integer of 1 to 3), and R 6 is a hydrogen or methyl group And R 7 is hydrogen or halogen, in the above formula Is a single bond or a double bond).
- the pharmaceutical composition for the treatment of multiple sclerosis based on the AMPK inhibitory function and zinc homeostasis control function of the present invention made as described above is treated with a novel compound having AMPK activity inhibitory function and zinc homeostasis control function to prevent spinal cord injury due to multiple sclerosis. It can be used to develop new treatments that can overcome behavioral disorders. Of course, the scope of the present invention is not limited by these effects.
- 1A is a diagram showing a timeline for an experimental design according to an embodiment of the present invention.
- 1H10 was administered intraperitoneally once a day, and mice were sacrificed 21 days after immunization.
- 1B is a graph analyzing EAE clinical scores for the vehicle administration group.
- 1C is a graph analyzing EAE clinical scores for the 1H10 administration group.
- FIG. 2A is a microscopic photograph observing representative microglia/macrophage activation in the spinal cord of sham-operated and MOG35-55 immunized mice (vehicle or 1H10). F4/80 (red), DAPI-stained nuclei (blue), and demyelinated regions were confirmed by reduced MBP staining (green). Scale bar, 50 ⁇ m.
- 2D is a representative image of Iba-1- (green) and CD68- (red) immune positive cells as images merged into vehicle- and 1H10-treated EAE mice. Nuclei stained with DAPI (blue). Scale bar, 50 ⁇ m.
- Figure 2g is a graph analyzing the colocalization scatterplots of Iba-1 with CD68.
- 3A is a micrograph showing a spinal cord section stained for cresyl violet to detect infiltration of SMS mononuclear cells. Scale bar, 100 ⁇ m.
- 3C is a micrograph showing the expression of T and B cells stained with antibodies to cell surface molecules such as CD4, CD8 and CD20.
- 3D is a graph analyzing the intensity of CD4, CD8 and CD20 immune responses in the thoracic spinal cord treated with or without 1H10 in sham-operated or EAE mice.
- 3E is a graph analyzing the percent area of CD4, CD8 and CD20 immune responses in the thoracic spinal cord treated with or without 1H10 in sham-operated or EAE mice.
- 3F is a representative immunofluorescence image showing CD8+ T cells co-labeled with phospho-AMPK ⁇ 1/2 in the spinal cord from vehicle- and 1H10-treated EAE mice.
- 3G is a graph showing the analysis of colocalization scatterplots of phospho-AMPK ⁇ 1/2 and CD8.
- 4A is a photomicrograph showing a portion of the spinal cord stained with TSQ to detect zinc accumulation. Scale bar, 100 ⁇ m.
- 4B is a micrograph showing a portion of the spinal cord stained for anti-mouse immunoglobulin G (IgG) to detect endogenous IgG. Scale bar, 100 ⁇ m.
- IgG immunoglobulin G
- 4E is a double-labeled confocal micrograph of CD31 + endothelial cells (red) and endogenous mouse IgG molecules (green) in the white matter of the spinal cord from vehicle- and 1H10-treated EAE mice. Scale bar, 20 ⁇ m.
- Figure 4f is an immunofluorescence image showing the expression of MMP-9 in the white matter of the spinal cord. Scale bar, 50 ⁇ m.
- Figure 5a is a graph showing the expression of the fluorescent substance FluoZin-3 as verified by the 1H10 treatment of the present invention to control the homeostasis of zinc.
- FIG. 5B is a graph showing the expression of free zinc fluorescently labeled drug (FluoZin-3) to verify the regulation of zinc homeostasis according to the 1H10 treatment of the present invention.
- 6A is a timeline showing the experimental design by analyzing the long-term protection effect of 1H10 after EAE induction. After 1H10 was administered intraperitoneally once a day for the entire period, mice were sacrificed 45 days after the initial immunization.
- 6B is a graph analyzing the long-term protective effect of 1H10 after induction of EAE, and analyzing the EAE clinical score for the vehicle.
- Figure 6c is a graph analyzing the long-term protective effect of 1H10 after EAE induction, and analyzing the EAE clinical score for the 1H10 administration group.
- FIG. 7 is a diagram of the results of research showing that loss of homeostasis of zinc may cause multiple sclerosis.
- MS multiple sclerosis
- 9 is a graph analyzing the neuroprotective effect of 25 similar compounds having a similar structure based on the structural similarity of 1H10 of the present invention.
- 10 is a graph analyzing the inhibitory effect of oxidative stress according to 25 novel compounds and 1H10 treatment.
- 11 is a graph analyzing the inhibitory effect of oxidative stress according to 8 novel compounds and 1H10 treatment.
- 12 is a graph analyzing the effect of inhibiting excitotoxicity according to 8 novel compounds and 1H10 treatment.
- 13 is a graph analyzing the effect of inhibiting apoptosis according to 8 novel compounds and 1H10 treatment.
- 14 is a graph showing the results of a zinc binding assay according to 25 novel compounds and 1H10 treatment.
- 15 is a graph analyzing AMPK ⁇ 2 inhibitory activity according to 25 novel compounds and 1H10 treatment.
- 16 is a graph showing the results of self-toxicity analysis according to 4 novel compounds and 1H10 treatment.
- FIG. 17 is an immunofluorescence photograph of GFAP (green) as an analysis of the activity of astrocytes in spinal cord tissue according to the 1H10 treatment of the present invention.
- GFAP green
- an abnormal increase astrogliosis
- MOG35-55 immunized mice vehicle or 1H10 was observed.
- Scale bar 50 ⁇
- FIG. 19 shows expression of IFN gamma and TNF alpha among cytokines in the spinal cord of the mouse on the 21st day after induction of EAE mice.
- IFN- ⁇ , green C, H
- TNF- ⁇ , red tumor necrosis factor alpha
- D I
- double label confocal micrographs AE
- Nuclei stained with DAPI blue
- B G
- Scale bar 20 ⁇
- AMP-activated protein kinase as used herein is a heterologous trimer protein composed of a catalytic ⁇ subunit ( ⁇ 1 or ⁇ 2), and two regulatory subunits ( ⁇ and ⁇ ). AMPK is phosphorylated and activated when the cellular energy level is low, and again regulates cellular metabolism to regulate gene expression over a long period of time to restore the level of ATP. It is known that an increase in the AMP/ATP ratio, a change in cellular pH and redox state, and an increase in the creatine/phosphocreatine ratio activate AMPK.
- Zinc used in this document is a substance abundantly present in the entire body, including the central nervous system, and plays a very important role in synaptic plasticity and learning of nerve cells. However, excessive zinc accumulation or severe deficiency is toxic to neurons. Intracellular accumulation of zinc is a major cause of nerve damage after acute neurological diseases such as stroke, epilepsy, traumatic brain injury, and hypoglycemia, and occurs in Alzheimer's disease, a chronic disease. It is well known that it causes the generation of plaques.
- a pharmaceutical composition for the treatment of multiple sclerosis or encephalomyelitis containing a compound having the structure of the following formula 1 as an active ingredient:
- R 1 to R 5 are each independently hydrogen, a hydroxy group, a halogen, a substituted or unsubstituted alkyl group having 1 to 7 carbon atoms, a substituted alkoxy group having 1 to 7 carbon atoms, or an unsubstituted alkoxy group, an amine group.
- a carboxyl group or R 2 and R 3 together form a -O-(CH 2 ) n -O- ring or a substituted or unsubstituted benzene ring (n is an integer of 1 to 3)
- R 6 is hydrogen or a methyl group
- R 7 is hydrogen or halogen, in the above formula Is a single bond or a double bond).
- the unsubstituted alkyl group may be methyl, ethyl, propyl or butyl
- the substituted alkyl group is fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, or It may be iodomethyl, diiodomethyl, or triraiodomethyl
- the halogen may be fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).
- the compound is (5Z)-5-(1H-Indol-3-ylmethylene)-2-[2-(trifluoromethyl) phenyl]amino-1,3-thiazol-4(5H)-one,
- the compound may have an effect of preventing demyelination, a neuroprotective effect, reducing tissue damage, preventing apoptosis, or inhibiting inflammatory infiltration.
- a method for treating multiple sclerosis in a subject comprising administering to a subject suffering from multiple sclerosis a therapeutically effective amount of a compound having the structure of Formula 1 below:
- R 1 to R 5 are each independently hydrogen, a hydroxy group, a halogen, a substituted or unsubstituted alkyl group having 1 to 7 carbon atoms, a substituted alkoxy group having 1 to 7 carbon atoms or an unsubstituted alkoxy group, amine A group, a carboxyl group, or R 2 and R 3 together form a -O-(CH 2 ) n -O- ring or a substituted or unsubstituted benzene ring (n is an integer of 1 to 3), and R 6 is a hydrogen or methyl group And R 7 is hydrogen or halogen, in the above formula Is a single bond or a double bond).
- a method for treating encephalomyelitis in a subject comprising administering to a subject suffering from encephalomyelitis a therapeutically effective amount of a compound having the structure of Formula 1 below:
- R 1 to R 5 are each independently hydrogen, a hydroxy group, a halogen, a substituted or unsubstituted alkyl group having 1 to 7 carbon atoms, a substituted alkoxy group having 1 to 7 carbon atoms or an unsubstituted alkoxy group, amine A group, a carboxyl group, or R 2 and R 3 together form a -O-(CH 2 ) n -O- ring or a substituted or unsubstituted benzene ring (n is an integer of 1 to 3), and R 6 is a hydrogen or methyl group And R 7 is hydrogen or halogen, in the above formula Is a single bond or a double bond).
- R 1 to R 5 are each independently hydrogen, a hydroxy group, a halogen, a substituted or unsubstituted alkyl group having 1 to 7 carbon atoms, a substituted alkoxy group having 1 to 7 carbon atoms or an unsubstituted alkoxy group, amine A group, a carboxyl group, or R 2 and R 3 together form a -O-(CH 2 ) n -O- ring or a substituted or unsubstituted benzene ring (n is an integer of 1 to 3), and R 6 is a hydrogen or methyl group And R 7 is hydrogen or halogen, in the above formula Is a single bond or a double bond).
- R 1 to R 5 are each independently hydrogen, a hydroxy group, a halogen, a substituted or unsubstituted alkyl group having 1 to 7 carbon atoms, a substituted alkoxy group having 1 to 7 carbon atoms or an unsubstituted alkoxy group, amine A group, a carboxyl group, or R 2 and R 3 together form a -O-(CH 2 ) n -O- ring or a substituted or unsubstituted benzene ring (n is an integer of 1 to 3), and R 6 is a hydrogen or methyl group And R 7 is hydrogen or halogen, in the above formula Is a single bond or a double bond).
- the effective amount of the compound may vary depending on the type of the affected part of the patient, the application site, the number of treatments, the treatment time, the formulation, the condition of the patient, the type of adjuvant, and the like.
- the amount used is not particularly limited, but may be 0.01 ⁇ g/kg/day to 10 mg/kg/day.
- the daily dose may be administered once a day, divided into 2-3 times a day at appropriate intervals, or intermittently administered at intervals of several days.
- the compound may be contained in an amount of 0.1-100% by weight based on the total weight of the composition.
- the pharmaceutical composition of the present invention may further include suitable carriers, excipients, and diluents commonly used in the preparation of pharmaceutical compositions.
- suitable carriers, excipients, and diluents commonly used in the preparation of pharmaceutical compositions may be used in the preparation of pharmaceutical compositions.
- solid or liquid additives for preparation may be used in the preparation of pharmaceutical compositions.
- the additive for formulation may be either organic or inorganic.
- excipients include lactose, sucrose, sucrose, glucose, cornstarch, starch, talc, sorbit, crystalline cellulose, dextrin, kaolin, calcium carbonate, and silicon dioxide.
- a binder for example, polyvinyl alcohol, polyvinyl ether, ethyl cellulose, methyl cellulose, arabic rubber, tragacanth, gelatin, shellac, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, calcium citrate, And dextrin and pectin.
- the lubricant include magnesium stearate, talc, polyethylene glycol, silica, and hydrogenated vegetable oil. Any colorant that is permitted to be added to pharmaceuticals can be used. These tablets and granules can be appropriately coated with a sugar coat, gelatin coating, or other necessary. In addition, preservatives, antioxidants, etc. can be added as needed.
- the pharmaceutical composition of the present invention may be prepared in any formulation conventionally prepared in the art (for example, Remington's Pharmaceutical Science, the latest edition; Mack Publishing Company, Easton PA), and the form of the formulation is not particularly limited. . These formulations are described in Remington's Pharmaceutical Science, 15th Edition, 1975, Mack Publishing Company, Easton, Pennsylvania 18042 (Chapter 87: Blaug, Seymour), a formula generally known for all pharmaceutical chemistry.
- the compound in the pharmaceutical composition of the present invention, can be administered orally or parenterally, preferably parenteral administration by intravenous injection, subcutaneous injection, intracerebroventricular injection, and intracerebrospinal fluid injection. , It can be administered by intramuscular injection and intraperitoneal injection.
- Zinc Transporter 3 which is located at the nerve endings and regulates the movement of zinc transporter 3 (ZnT3), which is located at the nerve endings, suppresses the symptoms of multiple sclerosis and tissue damage of the spinal cord white matter. As the results are released one after another, interest in zinc and multiple sclerosis is increasing.
- nerve cell damage processes such as zinc neurotoxicity and excitatory toxicity are accompanied by a decrease in ATP and an increase in AMP, and the AMPK activity, which is activated by AMP, is evident, and when the increased AMPK activity is lowered, nerve cell damage is reduced.
- AMPK activity which is activated by AMP
- AMPK activity is associated with damage and pathological involvement of the central nervous system in neurodegenerative diseases such as dementia, Parkinson's disease, Huntington's chorea, and multiple sclerosis. Accordingly, the present inventors have conducted a study on the neurotoxic mechanism centered on AMPK, which is the most important in metabolic regulation, and based on the preceding research, the present inventors conducted a study on the development of a new AMPK inhibitor to screen for a new compound, and the AMPK inhibitor ((Z)-5 -((1H-indol-3-yl)methylene)-2-((3-hydroxyphenyl)amino)thiazol- 4(5H)-one, named "1H10", formula 2) was discovered.
- the present invention has shown that the 1H10 can suppress the onset of disease at various levels after induction of autoimmune encephalomyelitis (EAE), which is an animal model of multiple sclerosis. Specifically, 1H10 treatment showed excellent symptom relief effect in the behavioral experiment and the incidence rate was also suppressed. In addition, it was confirmed that demyelination and immune cell activity of the spinal cord were reduced, and immune cells were prevented from invading into the demyelinating site. This suggests that the 1H10 drug is related to the mechanism of inhibition of AMPK activity.
- EAE autoimmune encephalomyelitis
- the pharmaceutical composition for the treatment of multiple sclerosis based on the AMPK inhibitory function and zinc homeostasis control function of the present invention can overcome spinal cord damage and behavioral disorders caused by multiple sclerosis by treating a novel compound with AMPK activity inhibitory function and zinc homeostasis control function. It provides a new therapeutic agent that can be used.
- the novel drug can act as a zinc chelator in the process of nerve cell damage. In particular, in the case of 1H10, it can act as a zinc ionophore as well as chelation, so it can be developed as an active zinc homeostasis modulator.
- the experimental animal used in the present invention is an 8-week-old C57BL/6 female mouse supplied from Daehan Biolink. These mice were raised in an environment where temperature and humidity were controlled, and food and water were supplied freely.
- the mouse cortical neurons used in the present invention were extracted and cultured from the brain of a mouse embryo, and Dulbecco's modified Eagle's medium (DMEM, Gibco, Grand Island, NY) to which 5% fetal bovine serum (FBS) and 5% horse serum (HS) were added. , US) was incubated at 95% humidity, 5% CO 2 and 37°C temperature conditions. For activation and differentiation of the cells, the cells were proliferated at a density of 2 x 10 4 cells in a 24-well tissue culture plate and cultured in MEM medium without FBS and HS before treatment with zinc and compounds.
- DMEM Dulbecco's modified Eagle's medium
- FBS fetal bovine serum
- HS horse serum
- the present inventors induce an autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, by subcutaneous injection of Myelin oligodendrocyte glycoprotein 35-55 (MOG35-55) peptide antigen into C57BL/6 female mice (Fig. 1a).
- EAE autoimmune encephalomyelitis
- MOG35-55 Myelin oligodendrocyte glycoprotein 35-55
- CFA Complete freund's adjuvant
- mice were injected with the same amount of CFA containing MOG35-55 and Mycobacterium tuberculosis H37Ra in both sides.
- Pertussis toxin (4 ⁇ g/ml, List Biological Laboratories, USA) was injected intraperitoneally on the day of immunization and on the second day after immunization. After the immunization, the weight and clinical symptoms of the mice were measured every day, and the degree of progression of EAE was evaluated based on specific clinical symptoms. Details on this are described below.
- EAE clinical symptom evaluation used in the present invention was evaluated based on previous studies (Jones et al., J Neuroimmunol . Aug 13;199(1-2):83-93. 2008). Specifically, for the evaluation of clinical symptoms of EAE, the motion of the mice was evaluated daily according to the following criteria.
- score 0 no symptoms; score 0.5, partial paralysis of the tail or slight abnormal gait; score 1.0, complete or partial tail palsy and mild hindlimb palsy; score 1.5, complete tail palsy and mild hindlimb palsy; score 2.0, tail palsy and moderate hind limb weakness (proven that feet often fall out while walking in a cage); score 2.5, no weight in hind legs, but slight movement; score 3.0, complete hind limb paralysis; score 3.5, paralysis of the hind limbs and mild weakness in the forelimbs; score 4.0, limbs are completely paralyzed, but the head is moving; score 4.5, moribund state; score 5.0, death.
- the present inventors anesthetized mice with urethane on the 21st day after EAE induction, and then perfused with 4% paraformaldehyde to the heart to fix the spinal cord, and after extracting the spinal cord, mononuclear cells from the spinal cord The infiltrate was observed through cresyl violet staining.
- the spinal cord was cut to a thickness of 30 um in a cryostat, and the slices were obtained, and then placed on a gelatin-coated slide and dried at room temperature for 30 minutes. It was immersed in 100% and 70% ethanol solutions for 3 minutes each, followed by staining in 0.1% cresyl violet solution for 15 minutes.
- the present inventors On the 21st day after EAE induction, the present inventors anesthetized the mouse with urethane, and then perfused with 4% paraformaldehyde to the heart to fix the spinal cord, and after extracting the spinal cord, the infiltration of immune cells in the spinal cord was observed. To this end, immunohistochemistry was performed using CD4 and CD8 used as markers for T cells, and CD20 antibodies used as markers for B cells. The frozen sections were reacted with 3% hydrogen peroxide for 15 minutes at room temperature to remove endogenous peroxidase, and then the primary antibodies rat anti-CD4 (1:50, BD Bioscience, CA, USA), CD8 (1:50).
- IgG Immunoglobulin G
- the IgG is the most abundant immunoglobulin in plasma, and it is easy to identify it, so the presence of IgG in the spinal cord is used to monitor damage to the blood-brain barrier and extravasation of proteins (Ruth and Feinerman, Acta Neuropathol. 76(4): 380-7.1988).
- the frozen sections were reacted with biotinylated horse anti-mouse IgG (1:250, Vector Laboratories, USA) at room temperature for 2 hours and then reacted with ABC regent in the same manner as above, and then colored with DAB solution.
- the present inventors anesthetized mice with urethane on the 21st day after EAE induction, and then perfused with 4% paraformaldehyde to the heart to fix the spinal cord.After the spinal cord was excised, the tissue demyelination and microglia Immunofluorescence staining was performed with myelin basic protein (MBP) and F4/80 (Microglia/Macrophage) antibodies to test the activity of cells/macrophages.
- MBP myelin basic protein
- F4/80 Microglia/Macrophage
- Iba-1 Ionized calcium binding adapter molecule-1
- CD68 which are used as markers for microglia/macrophages, are used as markers for microglia/macrophages to analyze the phenotype of strongly active microglia/macrophages in the white matter part of the damaged spinal cord.
- Cluster of Differentiation 68 Biimmunofluorescence staining was performed using an antibody.
- AMPK AMP-activated protein kinase
- Matrix metallopeptidase 9 In order to compare and analyze the activity of (MMP-9), immunofluorescence staining was performed using an MMP-9 antibody. To test the activity of astrocytes in the spinal cord, immunofluorescence staining was performed using an antibody of glial fibrillary acidic protein (GFAP), and the expression of cytokines such as tumor necrosis factor (TNF) alpha and interferon (IFN) gamma were compared and analyzed. For this, double immunofluorescence staining was performed using TNF-alpha and IFN gamma antibodies.
- GFAP glial fibrillary acidic protein
- TNF tumor necrosis factor
- IFN interferon
- the frozen sections were reacted with 3% hydrogen peroxide for 15 minutes at room temperature to remove endogenous peroxidase, and then the primary antibody, rat anti-MBP (1:200, Abcam, UK).
- the present inventors examined the spinal cord tissue after the evaluation of clinical symptoms of EAE-induced mice was completed by the histochemical method of N-(6 methoxy 8 quinolyl) para toluenesulfonamide (TSQ), which is a zinc staining method.
- TSQ N-(6 methoxy 8 quinolyl) para toluenesulfonamide
- zinc is present at the end of the nerve axons in gray matter, and only very small amounts are observed in the white matter.
- the mice were anesthetized with 5% isoflurane, and the spinal cord was removed without perfusion and rapidly cooled with dry ice. The unfixed frozen tissue was cut to a thickness of 20 ⁇ m in a -15°C cryostat to obtain a section.
- TSQ fluorescence was observed using an Olympus IX70 fluorescence microscope with a wavelength of 360 nm/490 nm and evaluated using an INFINITY3-1 CCD cooled digital color camera (Lumenera Co., Canada) and INFINITY analysis software.
- FluoZin-3 a substance that shows fluorescence when bound to free zinc, was treated on neurons of cultured mice, exposed to zinc (300 ⁇ M) for 15 minutes, and then the zinc was removed. The zinc concentration in nerve cells was measured for 60 minutes.
- the present inventors observed the demyelination of spinal cord tissue and the activity of microglia/macrophages through immunofluorescence staining.
- the white matter of the spinal cord to be stained in green color
- the green staining was lowered in the tissues of EAE mice, and the red color indicating the activity of microglia/macrophages appeared strongly (FIG. 2A).
- the decrease in MBP means that myelin covering the axon of the nerve is damaged (FIG. 2B).
- the EAE-induced demyelination and microglia/macrophage activity were significantly reduced in the spinal cord of animals to which 1H10 was continuously administered (FIG. 2C).
- the present inventors observed the activity of astrocytes in spinal cord tissue through immunofluorescence staining. As a result, it was confirmed that the green color indicating the activity of astrocytes was strongly distributed in the spinal cord white matter (white matte) of the experimental group in which EAE was induced, whereas the activity of astrocytes was significantly suppressed in the experimental group administered with 1H10 (Fig. 17 and 18).
- the present inventors observed the invasion of monocytes in the spinal cord of the mouse on the 21st day after induction of EAE mice by cresyl violet staining.
- AMPK activity is known to enhance the survival of T cells.
- phosphorylation of AMPK in CD8(+) T cells infiltrated into the spinal cord after EAE induction was increased, but was observed to be significantly decreased in the experimental group to which 1H10 was administered (FIGS. 3f to 3h).
- the above results suggest that inhibition of AMPK by 1H10 of the present invention can alleviate symptoms of EAE by reducing the survival of autoreactive T cells infiltrated into the spinal cord.
- the present inventors observed expression of IFN gamma and TNF alpha among cytokines in the spinal cord of the mouse on the 21st day after induction of EAE mice through immunofluorescence staining. As a result, it was observed that the expression of IFN gamma in the spinal cord white matter was increased in the experimental group to which 1H10 was administered after EAE induction, whereas the expression of TNF alpha was decreased (FIGS. 19 and 20).
- the present inventors observed abnormal accumulation of zinc in the EAE-induced spinal cord white matter, damage to the blood brain barrier (BBB), and the activity of MMP-9 by the administration of 1H10.
- mice administered with vehicle or mice administered with only 1H10 mice administered with only 1H10 (Sham group)
- IgG staining due to BBB damage was not found in white matter or gray matter.
- mice 3 weeks after injection of MOG IgG infiltration was significantly increased in both white matter and gray matter, and this phenomenon was found to be significantly reduced by the administration of 1H10 (FIGS. 4c to 4e).
- the present inventors administered 1H10 intraperitoneally once a day for the entire period after induction of mouse EAE, and then sacrificed the mouse 45 days after the initial immunization to observe clinical symptoms and incidence (FIG. 6A), and 1H10 was administered. It was observed that the clinical symptoms and incidence rate significantly decreased in the experimental group (FIGS. 6b to 6d). This proves that the administration of 1H10 is effective in relieving the symptoms of EAE for a long time in the acute phase (21 days) as well as the chronic phase (45 days).
- 1H10 of the present invention based on the structural similarity of 1H10 of the present invention, 25 similar compounds having similar structures were purchased from a compound library manufacturer (InterBioScreen, Russia; Akos, Germany). Thereafter, ZnCl 2 (400 ⁇ M) was treated for 10 minutes to induce zinc toxicity in the cerebral cortical neurons of the cultured mice, and after 12.5 hours, the selected 25 compounds and the previously selected drug 1H10 were used. Treatment (20 ⁇ M) was performed and the inhibition of cell death was observed through cell viability assay (Cell Counting Kit-8, Dojindo).
- the present inventors observed the effects of inhibiting oxidative stress in addition to zinc toxicity for the eight drugs and 1H10 of the above examples. Specifically, oxidative damage induced neurotoxicity by treating the cortical neurons of mice with H 2 O 2 (100 ⁇ M) and FeCl 2 (100 ⁇ M) for about 4 hours and 20 hours, respectively, and the selected 8 drugs and 1H10 was treated (20 ⁇ M). After that, cytotoxicity was observed through LDH (Lactate Dehydrogenase) analysis.
- LDH Lacate Dehydrogenase
- the present inventors observed the effect of inhibiting excitotoxicity on the 8 drugs of the above example and 1H10. Specifically, excitotoxicity was induced by treatment with NMDA (N-methyl-D-aspartate, 50 ⁇ M) on the cortical neurons of mice for 3 hours, and treatment with the selected 8 drugs and 1H10 (20 ⁇ M) and LDH cells As a result of observing toxicity, 6 drugs (4B01, 4B08, 4C01, 4C03, 4C04, 4C08) except for 4B04 and 4C06 were found to significantly inhibit excitatory toxicity by NMDA (FIG. 12).
- the present inventors observed the effect of inhibiting apoptosis on the 8 drugs of the above example and 1H10. Specifically, neurotoxicity caused by apoptosis was induced by treatment with Etoposide (ETPS, 10 ⁇ M) on cortical neurons of mice for 20 hours. Thereafter, the selected 8 drugs and 1H10 were treated (20 ⁇ M) and LDH cytotoxicity was observed. As a result, 5 drugs (4B01, 4B08, 4C01, 4C06, 4C08) except 4B04, 4C03, 4C04 showed ETPS toxicity. It was found to significantly inhibit (Figure 13).
- Etoposide Etoposide
- the present inventors measured the recombinant AMPK ⁇ 2 enzyme activity by treatment with 1H10 and 25 compounds (10 ⁇ M each) and the previously well-known AMPK inhibitor compound C (CC, 10 ⁇ M) through KinaseProfilerTM Service (Eurofins, UK). As a result, 4A06, 4B02, 4C04, 4C05, 4C06, 4C08, 4D01 showed similar AMPK inhibitory effects to 1H10 (FIG. 15).
- the present inventors determined the self-toxicity of 4 drugs (4B01, 4B08, 4C01, 4C08) that showed a protective effect in common against all cytotoxicity (zinc toxicity, oxidative damage, excitotoxicity, apoptosis) with 1H10. Compared. Specifically, in the cerebral cortical neuron culture of mice, each 40 ⁇ M of the drug was treated and LDH cytotoxicity was observed after 24 or 48 hours.
- the compounds according to an embodiment of the present invention have protective effects on various toxic mechanisms such as excitotoxicity, oxidative stress, apoptosis, and zinc neurotoxicity related to conventional multiple sclerosis.
- MMP-9 activity was reduced through zinc chelation to prevent the permeation and accumulation of immune cells in the white matter of the spinal cord, thereby reducing the autoimmune response, thereby suppressing the occurrence of multiple sclerosis disease. Therefore, 1H10 of the present invention can be used in the development of drugs capable of replacing steroids and immunosuppressants having serious side effects due to long-term administration and controlling fundamental problems.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
코드명 | 구조식 | IUPAC 명칭 |
4-A01 | (5Z)-5-(1H-Indol-3-ylmethylene)-2-{[2-(trifluoromethyl)phenyl]amino}-1,3-thiazol-4(5H)-one | |
4-A02 | (5Z)-5-(1H-Indol-3-ylmethylene)-2-{[3-(trifl(uoromethyl)phenyl]amino}-1,3-thiazol-4(5H)-one | |
4-A03 | (5Z)-2-[(3-Bromophenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one | |
4-A04 | (5Z)-5-(1H-Indol-3-ylmethylene)-2-[(4-methylphenyl)amino]-1,3-thiazol-4(5H)-one | |
4-A05 | (5Z)-5-(1H-Indol-3-ylmethylene)-2-[(3-methylphenyl)amino]-1,3-thiazol-4(5H)-one | |
4-A06 | (5Z)-2-Anilino-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one | |
4-A07 | (5Z)-2-[(2,4-Dimethylphenyl)amino]-5-(1H-in dol-3-ylmethylene)-1,3-thiazol-4(5H)-one |
|
4-A08 | (5Z)-2-[(2-Chlorophenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one | |
4-B01 | (5Z)-2-[(3,4-Dimethylphenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one | |
4-B02 | (5Z)-2-[(4-Hydroxyphenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one | |
4-B03 | (5Z)-5-(1H-Indol-3-ylmethylene)-2-[(2-methylphenyl)amino]-1,3-thiazol-4(5H)-one | |
4-B04 | (5Z)-2-[(2,3-Dimethylphenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one | |
4-B05 | (5E)-5-(1H-Indol-3-ylmethylene)-2-(1-naphthylamino)-1,3-thiazol-4(5H)-one | |
4-B06 | (5Z)-2-[(3-Chlorophenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one | |
4-B07 | (2E,5E)-5-((5-bromo-1H-indol-3-yl)methylene)-2-(phenylimino)thiazolidin-4-one | |
4-B08 | (2Z,5E)-5-((1H-indol-3-yl)methylene)-2-((4-butylphenyl)imino)thiazolidin-4-one | |
4-C01 | (Z)-5-((1H-indol-3-yl)methylene)-2-((4-butylphenyl)amino)thiazol-4(5H)-one | |
4-C02 | (Z)-5-((1H-indol-3-yl)methylene)-2-((3-methoxyphenyl)amino)thiazol-4(5H)-one | |
4-C03 | (2E,5Z)-5-((2-methyl-1H-indol-3-yl)methylene)-2-(p-tolylimino)thiazolidin-4-one | |
4-C04 | (2Z,5E)-5-((2-methyl-1H-indol-3-yl)methylene)-2-(p-tolylimino)thiazolidin-4-one | |
4-C05 | (Z)-3-((5-((1H-indol-3-yl)methylene)-4-oxo-4,5-dihydrothiazol-2-yl)amino)benzoic acid | |
4-C06 | (E)-2-((5-((1H-indol-3-yl)methylene)-4-oxo-4,5-dihydrothiazol-2-yl)amino)benzoic acid | |
4-C07 | (2Z,5Z)-2-((2-chlorophenyl)imino)-5-((2-methyl-1H-indol-3-yl)methylene)thiazolidin-4-one | |
4-C08 | (Z)-5-((5-((1H-indol-3-yl)methylene)-4-oxo-4,5-dihydrothiazol-2-yl)amino)-2-hydroxybenzoic acid | |
4-D01 | (Z)-5-((1H-indol-3-yl)methylene)-N-(benzo[d][1,3]dioxol-5-yl)-4-methylene-4,5-dihydrothiazol-2-amine |
Claims (11)
- 본 발명의 일 관점에 따르면, 하기 화학식 1의 구조를 갖는 화합물을 유효성분으로 함유하는, 다발성 경화증 또는 뇌척수염 치료용 약학적 조성물이 제공된다:(화학식 1)
- 제1항에 있어서,상기 치환되지 않은 알킬기는 메틸, 에틸, 프로필 또는 부틸인, 조성물.
- 제1항에 있어서,상기 치환된 알킬기는 플루오로메틸, 디플루오로메틸, 트리플루오로메틸기, 클로로메틸, 디클로로메틸, 트리클로로메틸 또는 아이오도메틸, 디아이오도메틸, 또는 트리라아이오도메틸인, 조성물.
- 제1항에 있어서,상기 할로겐은 불소(F), 염소(Cl), 브롬(Br) 또는 요오드(I)인, 조성물.
- 제1항에 있어서,상기 화합물은 (5Z)-5-(1H-Indol-3-ylmethylene)-2-{[2-(trifluoromethyl) phenyl]amino}-1,3-thiazol-4(5H)-one,(5Z)-5-(1H-Indol-3-ylmethylene)-2-{[3-(trifluoromethyl)phenyl]amino}-1,3-thiazol-4(5H)-one,(5Z)-2-[(3-Bromophenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one,(5Z)-5-(1H-Indol-3-ylmethylene)-2-[(4-methylphenyl)amino]-1,3-thiazol-4(5H)-one,(5Z)-5-(1H-Indol-3-ylmethylene)-2-[(3-methylphenyl)amino]-1,3-thiazol-4(5H)-one,(5Z)-2-Anilino-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one,(5Z)-2-[(2,4-Dimethylphenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one,(5Z)-2-[(2-Chlorophenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one,(5Z)-2-[(3,4-Dimethylphenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one,(5Z)-2-[(4-Hydroxyphenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one,(5Z)-5-(1H-Indol-3-ylmethylene)-2-[(2-methylphenyl)amino]-1,3-thiazol-4(5H)-one,(5Z)-2-[(2,3-Dimethylphenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one,(5E)-5-(1H-Indol-3-ylmethylene)-2-(1-naphthylamino)-1,3-thiazol-4(5H)-one,(5Z)-2-[(3-Chlorophenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one,(5E)-2-Anilino-5-[(5-bromo-1H-indol-3-yl)methylene]-1,3-thiazol-4(5H)-one,(5E)-2-[(4-Butylphenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one,(5Z)-2-[(4-Butylphenyl)amino]-5-(1H-indol-3-ylmethylene)-1,3-thiazol-4(5H)-one,(5Z)-5-(1H-Indol-3-ylmethylene)-2-[(3-methoxyphenyl)amino]-1,3-thiazol-4(5H)-one,(5Z)-5-[(2-Methyl-1H-indol-3-yl)methylene]-2-[(4-methylphenyl)amino]-1,3-thiazol-4(5H)-one,(5E)-5-[(2-Methyl-1H-indol-3-yl)methylene]-2-[(4-methylphenyl)amino]-1,3-thiazol-4(5H)-one,3-{[(5Z)-5-(1H-Indol-3-ylmethylene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]amino}benzoic acid,2-{[(5E)-5-(1H-Indol-3-ylmethylene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]amino}benzoic acid,(5Z)-2-[(2-Chlorophenyl)amino]-5-[(2-methyl-1H-indol-3-yl)methylene]-1,3-thiazol-4(5H)-one,2-Hydroxy-5-{[(5Z)-5-(1H-indol-3-ylmethylene)-4-oxo-4,5-dihydro-1,3-thiazol-2-yl]amino}benzoic acid,(2E,5E)-5-((5-bromo-1H-indol-3-yl)methylene)-2-(phenylimino)thiazolidin-4-one,(2Z,5E)-5-((1H-indol-3-yl)methylene)-2-((4-butylphenyl)imino)thiazolidin-4-one,(Z)-5-((1H-indol-3-yl)methylene)-2-((4-butylphenyl)amino)thiazol-4(5H)-one,(Z)-5-((1H-indol-3-yl)methylene)-2-((3-methoxyphenyl)amino)thiazol-4(5H)-one,(2E,5Z)-5-((2-methyl-1H-indol-3-yl)methylene)-2-(p-tolylimino)thiazolidin-4-one,(2Z,5E)-5-((2-methyl-1H-indol-3-yl)methylene)-2-(p-tolylimino)thiazolidin-4-one,(Z)-3-((5-((1H-indol-3-yl)methylene)-4-oxo-4,5-dihydrothiazol-2-yl)amino)benzoic acid,(E)-2-((5-((1H-indol-3-yl)methylene)-4-oxo-4,5-dihydrothiazol-2-yl)amino)benzoic acid,(2Z,5Z)-2-((2-chlorophenyl)imino)-5-((2-methyl-1H-indol-3-yl)methylene)thiazolidin-4-one,(Z)-5-((5-((1H-indol-3-yl)methylene)-4-oxo-4,5-dihydrothiazol-2-yl)amino)-2-hydroxybenzoic acid 또는(Z)-5-((1H-indol-3-yl)methylene)-N-(benzo[d][1,3]dioxol-5-yl)-4-methylene-4,5-dihydrothiazol-2-amine인, 조성물.
- 제1항에 있어서,상기 화합물은(Z)-5-((1H-indol-3-yl)methylene)-2-((3,4-dimethylphenyl)amino)thiazol-4(5H)-one,(2Z,5E)-5-((1H-indol-3-yl)methylene)-2-((4-butylphenyl)imino)thiazolidin-4-one,(Z)-5-((1H-indol-3-yl)methylene)-2-((4-butylphenyl)amino)thiazol-4(5H)-one,(2E,5Z)-5-((2-methyl-1H-indol-3-yl)methylene)-2-(p-tolylimino)thiazolidin-4-one,(2Z,5E)-5-((2-methyl-1H-indol-3-yl)methylene)-2-(p-tolylimino)thiazolidin-4-one,(Z)-5-((5-((1H-indol-3-yl)methylene)-4-oxo-4,5-dihydrothiazol-2-yl)amino)-2-hydroxybenzoic acid 또는(Z)-5-((1H-indol-3-yl)methylene)-2-((3-hydroxyphenyl)amino)thiazol-4(5H)-one인, 조성물.
- 제1항에 있어서,상기 화합물은 탈수초화방지(demyelination), 신경보호효과(neuroprotective effect), 조직손상의 감소, 세포사멸(apoptosis) 방지 또는 염증성침윤(Inflammatory infiltration)의 억제효과를 갖는, 조성물.
- 치료적으로 유효한 양의 하기 화학식 1의 구조를 갖는 화합물을 다발성 경화증에 걸린 개체에 투여하는 단계를 포함하는 상기 개체의 다발성 경화증 치료방법:(화학식 1)
- 치료적으로 유효한 양의 하기 화학식 1의 구조를 갖는 화합물을 뇌척수염에 걸린 개체에 투여하는 단계를 포함하는 상기 개체의 뇌척수염 치료방법:(화학식 1)
- 다발성 경화증 치료에 사용되는 하기 화학식 1의 구조를 갖는 화합물:(화학식 1)
- 뇌 척수염 치료에 사용되는 하기 화학식 1의 구조를 갖는 화합물:(화학식 1)
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20887409.9A EP4066832A4 (en) | 2019-11-14 | 2020-11-12 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLERosis BASED ON AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION |
JP2022528544A JP7398840B2 (ja) | 2019-11-14 | 2020-11-12 | Ampk抑制機能と亜鉛恒常性調節機能に基づく多発性硬化症治療用の薬学的組成物 |
US17/776,693 US20230000839A1 (en) | 2019-11-14 | 2020-11-12 | Pharmaceutical composition for treating multiple sclerosis on basis of ampk inhibitory function and zinc homeostasis control function |
KR1020227017186A KR20220088750A (ko) | 2019-11-14 | 2020-11-12 | Ampk 억제기능과 아연항상성 조절기능에 기반한 다발성 경화증 치료용 약학적 조성물 |
CN202080093043.2A CN114929217A (zh) | 2019-11-14 | 2020-11-12 | 基于ampk抑制功能和锌稳态控制功能用于治疗多发性硬化的药物组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0145709 | 2019-11-14 | ||
KR20190145709 | 2019-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021096270A1 true WO2021096270A1 (ko) | 2021-05-20 |
Family
ID=75911395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/015932 WO2021096270A1 (ko) | 2019-11-14 | 2020-11-12 | Ampk 억제기능과 아연항상성 조절기능에 기반한 다발성 경화증 치료용 약학적 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230000839A1 (ko) |
EP (1) | EP4066832A4 (ko) |
JP (1) | JP7398840B2 (ko) |
KR (1) | KR20220088750A (ko) |
CN (1) | CN114929217A (ko) |
WO (1) | WO2021096270A1 (ko) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012080729A2 (en) * | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
KR101324647B1 (ko) | 2010-12-10 | 2013-11-01 | 한국과학기술연구원 | 다발성신경경화증의 치료 또는 예방용 조성물 및 이의 스크리닝 방법 |
CN104059060A (zh) * | 2014-05-30 | 2014-09-24 | 西安交通大学 | 一种5-(1h-吲哚-3-亚甲基)-1,3-噻唑烷-4-酮类衍生物及其合成方法和应用 |
KR20180018343A (ko) * | 2016-08-09 | 2018-02-21 | 세종대학교산학협력단 | Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4255419A (en) * | 1979-09-27 | 1981-03-10 | Allergan Pharmaceuticals, Inc. | Zinc deficiency in multiple sclerosis |
CA2496772A1 (en) * | 2002-08-29 | 2004-03-11 | Rob Hooft Van Huijsduijnen | Protein tyrosine phosphatase inhibitors |
GB0915892D0 (en) * | 2009-09-10 | 2009-10-14 | Smithkline Beecham Corp | Compounds |
EP2685976B1 (en) * | 2011-03-17 | 2017-12-27 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Quinolone analogs for treating autoimmune diseases |
-
2020
- 2020-11-12 US US17/776,693 patent/US20230000839A1/en active Pending
- 2020-11-12 JP JP2022528544A patent/JP7398840B2/ja active Active
- 2020-11-12 KR KR1020227017186A patent/KR20220088750A/ko unknown
- 2020-11-12 WO PCT/KR2020/015932 patent/WO2021096270A1/ko unknown
- 2020-11-12 CN CN202080093043.2A patent/CN114929217A/zh active Pending
- 2020-11-12 EP EP20887409.9A patent/EP4066832A4/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101324647B1 (ko) | 2010-12-10 | 2013-11-01 | 한국과학기술연구원 | 다발성신경경화증의 치료 또는 예방용 조성물 및 이의 스크리닝 방법 |
WO2012080729A2 (en) * | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
CN104059060A (zh) * | 2014-05-30 | 2014-09-24 | 西安交通大学 | 一种5-(1h-吲哚-3-亚甲基)-1,3-噻唑烷-4-酮类衍生物及其合成方法和应用 |
KR20180018343A (ko) * | 2016-08-09 | 2018-02-21 | 세종대학교산학협력단 | Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 |
Non-Patent Citations (12)
Title |
---|
"Remington's Pharmaceutical Science", 1975, MACK PUBLISHING COMPANY, pages: 18042 |
CHOI BO YOUNG, JEONG JEONG HYUN, EOM JAE-WON, KOH JAE-YOUNG, KIM YANG-HEE, SUH SANG WON: "A Novel Zinc Chelator, 1H10, Ameliorates Experimental Autoimmune Encephalomyelitis by Modulating Zinc Toxicity and AMPK Activation", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 21, no. 9, 10 May 2020 (2020-05-10), pages 3375, XP055813395, DOI: 10.3390/ijms21093375 * |
CHOI, B. Y. ET AL., J. NEUROINFLAMMATION., vol. 12, 2015, pages 104 |
CHOI, B. Y. ET AL., NEUROBIOL. DIS., vol. 54, 2013, pages 382 - 391 |
CHOI, B. Y. ET AL., NEUROBIOL. DIS., vol. 94, 2016, pages 205 - 212 |
EOM J. W. ET AL., ACS CHEM NEUROSCI., vol. 10, no. 5, 2019, pages 2345 - 2354 |
EOM, J. W. ET AL., MOL. BRAIN., vol. 9, 2016, pages 14 |
JAE-WON EOM, TAE-YOUN KIM, BO-RA SEO, HWANGSEO PARK, JAE-YOUNG KOH, YANG-HEE KIM: "Identifying New AMP-Activated Protein Kinase Inhibitors That Protect against Ischemic Brain Injury", ACS CHEMICAL NEUROSCIENCE, AMERICAN CHEMICAL SOCIETY, US, vol. 10, no. 5, 15 May 2019 (2019-05-15), US, pages 2345 - 2354, XP055666338, ISSN: 1948-7193, DOI: 10.1021/acschemneuro.8b00654 * |
JONES ET AL., J. NEUROIMMUNOL., vol. 199, no. 1-2, 2008, pages 83 - 93 |
MANGALAM ASHUTOSH K., RATTAN RAMANDEEP, SUHAIL HAMID, SINGH JASPREET, HODA MD NASRUL, DESHPANDE MANDAR, FULZELE SADANAND, DENIC AL: "AMP-Activated Protein Kinase Suppresses Autoimmune Central Nervous System Disease by Regulating M1-Type Macrophage–Th17 Axis", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO., US, vol. 197, no. 3, 1 August 2016 (2016-08-01), US, pages 747 - 760, XP055813373, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1501549 * |
RUTHFEINERMAN, ACTA NEUROPATHOL., vol. 76, no. 4, 1988, pages 380 - 387 |
See also references of EP4066832A4 |
Also Published As
Publication number | Publication date |
---|---|
KR20220088750A (ko) | 2022-06-28 |
EP4066832A4 (en) | 2024-01-03 |
EP4066832A1 (en) | 2022-10-05 |
US20230000839A1 (en) | 2023-01-05 |
JP2023501814A (ja) | 2023-01-19 |
CN114929217A (zh) | 2022-08-19 |
JP7398840B2 (ja) | 2023-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018101708A1 (ko) | 미토콘드리아를 포함하는 약학 조성물 | |
WO2018097628A2 (ko) | 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법 | |
WO2018030879A1 (ko) | 아모디아퀸 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물 | |
WO2021010621A1 (ko) | 자가면역질환 및 염증성질환 펩타이드 치료제 | |
WO2020055166A1 (ko) | 벤즈히드릴 티오 아세트아미드 화합물을 유효성분으로 포함하는 섬유화 질환의 치료용 조성물 | |
WO2020235954A1 (en) | Administration method and dosage regimen for treatment of neurodegenerative diseases using trametinib and markers | |
WO2021096270A1 (ko) | Ampk 억제기능과 아연항상성 조절기능에 기반한 다발성 경화증 치료용 약학적 조성물 | |
WO2020073388A1 (zh) | 蒿甲醚在预防及治疗阿尔兹海默病中的应用 | |
WO2015050388A1 (ko) | 피마살탄을 포함하는 허혈성 뇌질환 예방 또는 치료용 약학적 조성물 | |
WO2020116810A1 (ko) | Fas 신호전달 억제용 펩티드를 포함하는 비만, 지방간 또는 지방간염의 예방 또는 치료용 약학적 조성물 | |
WO2009093864A2 (ko) | 뇌질환의 예방 또는 치료용 조성물 | |
WO2013051767A1 (ko) | 안지오제닌의 신규 용도 | |
WO2016133352A1 (ko) | 아모디아퀸을 유효성분으로 함유하는 대사성 질환의 예방, 개선, 또는 치료용 조성물 | |
WO2020091463A1 (ko) | 분리된 미토콘드리아를 포함하는 건병증 예방 또는 치료용 약학 조성물 | |
WO2022039421A1 (ko) | 아베마시클립을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 | |
WO2016043354A1 (ko) | 새로운 알츠하이머 질환 치료용 약학적 조성물 | |
WO2015111971A1 (ko) | Gpr119 리간드를 유효성분으로 포함하는 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물 | |
WO2020106048A1 (ko) | 퇴행성 신경질환의 예방 또는 치료용 약학 조성물 | |
WO2016122288A2 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
WO2020122392A1 (ko) | 조타로리무스를 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물 | |
WO2015108372A1 (ko) | 오스모틴을 포함하는 흥분독성 또는 시냅스 기능 장애에 의한 신경 질환의 예방 또는 치료용 조성물, 및 이를 이용한 신경 질환의 예방 또는 치료 방법 | |
WO2018026150A1 (en) | Pharmaceutical composition for prevention or treatment of neurodegenerative diseases | |
WO2023033534A1 (ko) | Kai1 폴리펩타이드를 포함하는 간 섬유화 억제용 약학 조성물 및 이의 용도 | |
WO2021256837A1 (ko) | 신장 질환 진단 또는 치료용 조성물 | |
WO2021006418A1 (ko) | 텐토닌의 단백질을 유효성분으로 포함하는 당뇨병 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20887409 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022528544 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227017186 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020887409 Country of ref document: EP Effective date: 20220617 |
|
ENP | Entry into the national phase |
Ref document number: 2020887409 Country of ref document: EP Effective date: 20220614 |